Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341441 · ClinicalTrials.gov registry record · Phase 3
Will Hydroxychloroquine Impede or Prevent COVID-19
A Phase 3 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 3
- Development phase
- 624
- Enrollment target
NCT04341441 is a Phase 3 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 624 participants.
The verdict
NCT04341441, a Phase 3 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 624 participants
- Enrollment target
Study Summary
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan, can prevent the acquisition, symptoms and clinical COVID-19 infection The primary objective of this study is to determine whether the use of daily or weekly oral hydroxychloroquine (HCQ) therapy will prevent SARS-CoV-2 infection and COVID-19 viremia and clinical COVID-19 infection healthcare workers (HCW) and first responders (FR) (EMS, Fire, Police, bus drivers) in Southeast Michigan. Preventing COVID-19 transmission to HCW, FR, and Detroit Department of Transportation (DDOT) bus drivers is a critical step in preserving the health care and first responder force, the prevention of COVID-19 transmission in health care facilities, with the potential to preserve thousands of lives in addition to sustaining health care systems and civil services both nationally and globally. If efficacious, further studies on the use of hydroxychloroquine to prevent COVID-19 in the general population could be undertaken, with a potential impact on hundreds of thousands of lives.
Interventions
- OTHER Placebo oral tablet
- DRUG Hydroxychloroquine - Daily Dosing
- DRUG Hydroxychloroquine - Weekly Dosing
- DIAGNOSTIC_TEST Monitoring Visit - Baseline
- DIAGNOSTIC_TEST Monitoring Visit - Week 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04341441
The ClinicalTrials.gov registry entry for NCT04341441 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo oral tablet is the first listed.
NCT04341441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04341441 about?
NCT04341441 is a clinical study titled "Will Hydroxychloroquine Impede or Prevent COVID-19". This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan, can prevent the acquisition, symptoms and cl...
What is the current status of trial NCT04341441?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2020-04-07. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT04341441?
The interventions under investigation include: Placebo oral tablet (OTHER), Hydroxychloroquine - Daily Dosing (DRUG), Hydroxychloroquine - Weekly Dosing (DRUG), Monitoring Visit - Baseline (DIAGNOSTIC_TEST), Monitoring Visit - Week 4 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04341441?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.